PaAMM-PEG-PGA as a drug carrier has the following advantages:
1.Versatility: The PAMAM branch structure in the PAMAM-PEG-PGA structure provides multiple drug loading sites, which can load multiple drugs simultaneously or sequentially, enabling multi-drug combination**. This versatility can improve the effectiveness and reduce the toxicity and toxicity of the drug.
2.Targeting: Targeting of specific cells or tissues can be achieved by introducing specific targeting ligands, such as antibodies, peptides, or low-molecular-weight targeting agents**, on the PAMM-PEG-PGA. This targeting can improve the effectiveness of the drug and reduce adverse effects on healthy tissue.
3.Controlled release: PAMAM-PEG-PGA has the ability to release drugs in a controlled manner. The drug can interact with the PAMAM moiety in the PAMM-PEG-PGA structure through physical adsorption, covalent bonding, or ion exchange, so as to achieve controlled release of the drug. This controlled release can prolong the duration of action of the drug and increase the bioavailability of the drug.
4.Cyclic stability: The introduction of PEG can increase the water solubility of PAMAM-PEG-PGA and improve its cyclic stability. PEG can form a protective layer that reduces the non-specific interaction of PAMM-PEG-PGA with blood components and prolongs the circulation time of the polymer in the body.
5.Biocompatibility and biodegradability: PAMAM-PEG-PGA has good biocompatibility and biodegradability. Glutamate, the degradation product of PGA, is degradable in vivo and has the effect of inhibiting tumor growth and regulating immune activity. This biocompatibility and biodegradability allows PAMAM-PEG-PGA to elicit significant toxicity and immune responses in vivo.
6.Flexibility and controllability: By modulating the structure and function of PAMAM-PEG-PGA, controlled drug release, cell targeting, and tissue engineering can be regulated. PAM-PEG-PGA with different structures and properties can be designed and synthesized according to specific application requirements to meet the needs of different drugs.
In summary, PAMAM-PEG-PGA has the advantages of versatility, targeting, controlled release, circulatory stability, biocompatibility and biodegradability as a drug carrier. These advantages make PAMM-PEG-PGA a potential drug carrier that can improve drug efficacy, reduce drug efficacy, and provide new pathways for specific diseases.